CH BIOTECH SER (08037) subsidiary Pengbo Hospital has reached cooperation agreements with OncoCare Hong Kong Cancer Center and United Family Healthcare Group to jointly establish a cross-border referral mechanism, marking a new chapter in international medical cooperation in BNCT.

At 34 years old, Russian physics professor Sergey was diagnosed with a rare and dangerous form of small cell carcinoma in the maxillary sinus. Seven rounds of chemotherapy and immunotherapy not only failed to control the disease but also left him with blurry vision and lost teeth. It was not until he learned from fellow patients that Hainan Boao Lecheng has the only institution in mainland China capable of conducting BNCT clinical treatment. In May of this year, Sergey traveled thousands of miles to Pengbo (Hainan) Boron Neutron Hospital. There was no surgery, no burning sensation from radiation therapy, just the low hum of equipmentafter 30 minutes, the treatment was over. He had no noticeable adverse effects post-treatment and felt in good spirits. Sergey is not alone. Since officially beginning to accept patients in March this year, Pengbo Hospital has completed nearly 50 cases of BNCT clinical treatments. Data from a three-month follow-up of the first 10 cases of head and neck cancer patients showed an objective response rate (ORR) of 80%4 complete responses and 4 partial responsesmarking the first time that BNCT clinical data from China has been publicly presented on the international stage. These patients all had head and neck cancers that were unresectable or late-stage relapses, where traditional chemotherapy or targeted therapies typically yield an ORR of only 10% to 20%. On September 2, Pengbo Hospital, under CH BIOTECH SER Holdings (08037), officially signed an agreement with OncoCare, a top oncology specialist institution in Hong Kong, to establish a two-way referral mechanism. As a member of the Tianma Medical Group, OncoCare operates five centers in Central and Tsim Sha Tsui, Hong Kong, serving over 20,000 patients annually. The group also collaborates closely with medical networks in Singapore, mainland China, Hong Kong, Malaysia, the Philippines, and Vietnam. Together, they will provide a comprehensive service chain: "overseas assessment + domestic treatment + overseas follow-up"Hong Kong doctors will first conduct remote MDT consultations for evaluation, and qualifying patients will fly directly to Hainan for BNCT treatment, followed by postoperative recovery and follow-up care by the Hong Kong team. Liu Xiaolin, chairman of CH BIOTECH SER's board, stated at the signing ceremony that the core of the cooperation involves four key elements: an international diagnosis and treatment collaborative green channel, normalization of international MDT consultations, joint research and real-world studies, and talent development and academic exchanges. "Today's agreement symbolizes not only trust but also responsibility." This cooperation also carries significant implications for bridging the "last mile" in cross-border medical treatment. Many patients worry about follow-up care after being treated in a foreign countrywho will monitor their condition? Who will handle subsequent tests? The collaboration between Pengbo and OncoCare precisely addresses this concern: patients will have Hong Kong professional doctors overseeing their journey from initial screening, treatment, to postoperative recovery, ensuring they continue to receive care and support upon returning home. Leveraging Hainan's zero-visa policy and the favorable medical conditions in the Lecheng Pilot Zone, the international patient pathway at Pengbo Hospital is expanding. Consultation bookings have reached thousands, including patients from the U.S., Vietnam, and Indonesia. With OncoCare's brand influence and patient network in Southeast Asia, Pengbo Hospital looks forward to attracting more patients from Singapore, Malaysia, and the Philippineswhere initial screenings and assessments can be completed locally, and patients can bypass to Hainan for treatment, followed by ongoing follow-up by the OncoCare medical team. This is the new model of cross-border healthcare, ensuring "patients do not get lost, and doctors stay connected." Commercial insurance coverage is also synchronized, further reducing the financial burden on patients. By July 2025, CH BIOTECH SER had signed a memorandum of cooperation with AXA Hong Kong, AXA Global Re, Qianhai Re, and Anruijia, to jointly develop an inclusive health insurance product that covers BNCT treatment expenses. In April this year, Chinas first specialized medical insurance product for BNCT was officially launched. With the enhancements in the commercial insurance systems in Hong Kong and Singapore through this collaboration, more patients will have access to this cutting-edge treatment at a lower economic threshold. Previously, Pengbo Hospital signed a strategic cooperation agreement with Beijing United Family Hospital Management Company to deepen collaboration and further expand the service network for BNCT in the domestic medical market. From Russia to Southeast Asia, from Hong Kong to the nationwide medical network, this cutting-edge technology, hailed as the "fifth method for cancer treatment," is progressively reaching global patients, leveraging the platform advantages of a Hong Kong-listed company.